Elevated free and bioavailable testosterone linked to non-alcoholic fatty liver disease risk in postmenopausal women
This prospective cohort study included 1,705 postmenopausal women in a community-based setting. Researchers assessed serum total testosterone, free testosterone, and bioavailable testosterone levels against non-alcoholic fatty liver disease progression over 5,269 person-years.
Higher concentrations and percentages of free testosterone and bioavailable testosterone were associated with increased risk of non-alcoholic fatty liver disease development. The odds ratio for free testosterone quartile 4 versus quartile 1 was 2.35 (95% CI 1.44-3.84). Bioavailable testosterone quartile 4 versus quartile 1 showed an odds ratio of 1.95 (95% CI 1.21-3.14). Total testosterone showed no significant association.
Conversely, higher free testosterone and bioavailable testosterone levels were associated with decreased probability of non-alcoholic fatty liver disease regression. The odds ratio for free testosterone quartile 4 versus quartile 1 was 0.56 (95% CI 0.33-0.95). Bioavailable testosterone quartile 4 versus quartile 1 had an odds ratio of 0.54 (95% CI 0.31-0.91). Adverse events and tolerability were not reported.
Limitations include the need for further studies in diverse populations and with longer follow-up periods. Findings need verification to determine broader implications. Free testosterone and bioavailable testosterone could be potential biomarkers for predicting non-alcoholic fatty liver disease progression. Associations were observed without explicit claims of causality.